New anti-diabetic agents — DPP-4 inhibitors: Viewing the advance of treatment for T2DM from pancreatic a-cells HONG Tian-pei. Department of Endocrinology, Peking University Third Hospital, Beijing 100191, China
【Summary】 Glucagon secreted from the pancreatic islet α cells is one of the factors resulting in elevated blood glucose. Glucagon-like peptide-1 (GLP-1) has an important role in the maintenance of blood glucose homeostasis through several mechanisms including inhibition of glucagon secretion from islet α cells. However, endogenous intact GLP-1 is degraded by dipeptidyl peptidease-4 (DPP-4) into inactive forms. DPP-4 inhibitors selectively block the activity of DPP-4 and prevent endogenous GLP-1 from quick inactivation. Therefore, DPP-4 inhibitors have been used as new agents for the treatment of T2DM.
【Key word】Pancreatic islet α cells; Glucagon; Glucagon-like peptide-1 (GLP-1); DPP-4 inhibitors; Diabetes mellitus, type 2